Company: LCTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0000950170-25-060090
Chunk: 67

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 67
---
 any officer, director, employee or consultant pursuant to the 2021 Plan that are contingent upon the approval of the Plan Amendment by our shareholders. We anticipate that stock options and restricted stock units may be granted in the discretion of our Board or the Compensation Committee under the 2021 Plan out of the additional common shares that would be available under the 2021 Plan if the Plan Amendment is approved by our shareholders; however, the number and type of equity-based awards that may be so granted has not yet been determined. However, pursuant to our current compensation arrangement for non-employee directors, and based on the current composition of our Board and taking into account the reduction in the size of our Board due to one director not standing for re-election at the Meeting, the aggregate number of our common shares subject to awards that will automatically be granted on an annual basis to all of our current directors who are not executive officers as a group will be 450,000 shares (which consists of a stock option to purchase 75,000 shares for each of our current non-employee directors who will continue in office following the Meeting). For additional information regarding our current compensation arrangement for non-employee directors, please see “Director Compensation” above.

<div align='center'>OUR BOARD RECOMMENDS A VOTE “FOR” THIS PROPOSAL

-49-</div>

EQUITY COMPENSATION PLAN INFORMATION The following table shows certain information concerning outstanding options and RSUs and the number of common shares remaining available for issuance and RSUs under all of our compensation plans and agreements as of December 31, 2024:

| Plan Category                                             |     | Number of    
 Shares to be 
 Issued Upon  
 Exercise of  
 Outstanding  
 Options and  
 Vesting of   
 Restricted   
 Stock Units, 
 and Rights   |            |     | Weighted       
 Average        
 Exercise Price 
 of the         
 Outstanding    
 Options,       
 and Rights     |      |     |    | Number of                 
 Shares                    
 Remaining                 
 Available for             
 Future Issuance           
 under Equity Compensation 
 Plans                     |            |
|:----------------------------------------------------------|:----|:-------------|-----------:|:----|:---------------|-----:|:----|---:|:--------------------------|-----------:|
| Equity compensation plans approved by shareholders (2)    |     |              | 25,372,326 |     | $              | 1.62 |     | -1 |                           | 21,877,761 |
| Equity compensation plans not approved by shareholders(3)